Pharyngeal Diseases - 48 Studies Found
| Not yet recruiting |
: A Study to Evaluate the Safety and Efficacy of Using the Combination Treatment of SHR-1210, Gemcitabine and Cis-platinum by Recurrent and Metastatic NPC Subjects : Nasopharyngeal Carcinoma : 2017-04-13 :
|
| Not yet recruiting |
: Measuring Patient-Reported Adverse Events in Oncology Practice Improves Quality of Life in Nasopharyngeal Carcinoma : Nasopharyngeal Neoplasms : 2017-03-16 :
|
| Not yet recruiting |
: Prospective Study for Molecular Biomarkers of Normal Nasopharyngeal Tissue : Nasopharyngeal Carcinoma : 2017-01-19 |
| Recruiting |
: High-activity Natural Killer Immunotherapy for Small Metastases of Nasopharyngeal Cancer : Metastatic Nasopharyngeal Cancer : 2016-12-30 : Biological: High-activity natural killer Each treatment: 8~10 billion cells in all, transfuion in 3 time |
| Not yet recruiting |
: A Study of Nasopharyngeal Carcinoma From Guangdong : Nasopharyngeal Cancer : 2016-12-18 |
| Recruiting |
: Chronomodulated Chemotherapy Followed by Concurrent Chemo-radiotherapy With IMRT in the Treatment of Advanced Nasopharyngeal Cancer : Esophageal Neoplasms [C06.405.117.430] : 2016-08-16 :
|
| Recruiting |
: A Trial of Endostar in Patients With Carcinoma of the Head and Neck : Nasopharyngeal Neoplasms : 2016-08-12 : Drug: Endostar The patients will be randomized to CRT arm and CRT+Endostar arm. All patients will receiv |
| Recruiting |
: Avelumab for Recurrent/Metastatic Nasopharyngeal Cancer : Nasopharyngeal Cancer : 2016-08-18 : Drug: Avelumab Avelumab 10mg/kg IV on days 1 and 15 of each 28-day cycle. Treatment will be given until |
| Active, not recruiting |
: A Study of ARGX-110 in Patients With Nasopharyngeal Carcinoma (NPC) : Cancer : 2016-04-22 : Drug: ARGX-110 |
| Recruiting |
: Study of Pembrolizumab (MK-3475) in Platinum Pre-treated Recurrent/Metastatic Nasopharyngeal Cancer (MK-3475-122, KEYNOTE-122) : Nasopharyngeal Neoplasms : 2015-11-19 :
|